EA
PTCT icon

Evolution Advisers’s PTC Therapeutics PTCT Stock Holding History

Evolution Advisers’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$0 Buy
+5
New +$361 ﹤0.01% 733

Other funds holding PTCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Evolution Advisers's PTCT Position: Q2 2026 in Review

Evolution Advisers opened a new position in PTC Therapeutics (PTCT) in Q2 2026: 5 shares worth $0. The stake represents ﹤0.01% of the portfolio and ranks #733 among its holdings.

381 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

  • Evolution Advisers held 5 shares of PTC Therapeutics worth $0 as of Q2 2026.
  • PTC Therapeutics was a new Evolution Advisers position in Q2 2026.
  • PTC Therapeutics made up ﹤0.01% of Evolution Advisers's portfolio in Q2 2026, its #733 holding.
  • 381 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on Evolution Advisers's 13F filing for Q2 2026, filed 31 Jul 2026.